Posted on

An athlete’s take on microdosing

Microdosing Mushrooms: Athlete Perspectives on the Psychedelic Supplement

A tiny dose of magic mushrooms might help you improve your form in the gym.

According to jiu jitsu athlete Adam Hanna, microdosing before a workout could help you focus on mind-body connection to better understand your body’s movement patterns.

“You are learning to do the same moves while under different states of consciousness, which helps you feel very small details,” he explains.

“Example: Exactly where my weight is in my fingers in a handstand. Is there enough weight in my thumb and index finger? You can hone in on stuff like this. It can help you really focus exclusively on tiny details that you don’t always think to do when sober.”

PDF of article

Posted on

US military to study psychedelic therapy?

GOP Congressman’s Amendment Would Direct Military To Study Psilocybin And MDMA Benefits For Service Members

Last week, an amendment calling for the Department of Defense (DOD) to study medical cannabis for military service members was approved by a House Committee.

Now, Rep. Matt Gaetz (R-FL) is pushing for the amendment to be expanded to include psilocybin and MDMA. If approved the DOD would be required to study the therapeutic potential of the drugs as alternatives to opioids prescribed for chronic pain.

PDF of article

Posted on

MAPS Raises Nearly $1.6 Million in Christie’s NFT Auction

MAPS Raises Nearly $1.6 Million in Christie’s NFT Auction

Historic Curated “Cartography of the Mind: A Curated NFT Sale” Auction is the First Time MAPS has Raised Money Using NFTs

Beeple’s PILGRIMAGE
Price Realized: $252,000

  • Digital art, inspired by personal experience and the potential of psychedelic healing, was donated by leading digital artists including Beeple, David Choe, and Alex Grey
  • Cartography of the Mind represented the single-largest sale of art to benefit MAPS in its 30+ year history of philanthropic art sales
  • Select pieces will be exhibited at Psychedelic Science 2023, marking the first time digital art will be exhibited in the extensive Psychedelic Science galleries and exhibits

The Multidisciplinary Association for Psychedelic Studies (MAPS) has announced that the recent curated digital art NFT sale – Cartography of the Mind: A Curated NFT Sale– raised $1,569,960. Proceeds of the auction, presented by Christie’s in collaboration with Ryan Zurrer, founder of Dialectic and Vine Ventures, will benefit MAPS.

On the heels of NFT.NYC, we were absolutely thrilled with the successful results of Cartography of the Mind: A Curated Sale to Benefit MAPS. Throughout the week, the physical exhibition at Christie’s new gallery on 6th Avenue drew impressive crowds of enthusiastic visitors. With competitive bidding, the sale realized over $1.5 million. It was 100% sold, and 130% sold hammer over low estimate. This is a true testament to the continued strength and vibrancy of the digital art market.

Nicole Sales, Christie’s Business Director of Digital Art

Digital artists from all over the world, including Beeple, David Choe, Alex Grey, Sarah Meyohas, Refik Anadol, Mad Dog Jones, and IX Shells, donated their art to support MAPS. The 501(c)(3) non-profit research, education, and advocacy organization was founded in 1986 and remains the leading body at the vanguard of research into potentially life-saving psychedelic-assisted therapies.

Psychedelic Healing is an artistic interpretation of the MAPS logo by renowned psychedelic artist Alex Grey. It was purchased by Ryan Zurrer, who donated it back to MAPS for the organization’s use and additional fundraising. Grey painted the original artwork to celebrate MAPS’ 35th anniversary in 2021; it is also available as a poster with proceeds benefiting MAPS and Grey’s Chapel of Sacred Mirrors.  

As a not-for-profit, we are always looking for innovative ways to fundraise, and working with this digital art community has truly been eye-opening. We are overwhelmed by the generosity and support from Ryan, Christie’s, and especially these incredible artists who put forth their art in support of our work in advancing psychedelic medicine. We have seen a significant overlap amongst people who have a passion for NFTs, blockchain, and psychedelics. All speak to the decentralized nature of experience, and we look forward to continuing to explore the intersection of both communities.

Rick Doblin, Ph.D., MAPS Founder and Executive Director

For those interested in seeing the art in person, it will be on display at Psychedelic Science 2023, the largest psychedelic gathering happening on June 17-25, 2023, in Denver. For those interested in learning more, contributing art or general participation, please visit psychedelicscience.org/participate

ABOUT MAPS
Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Since MAPS was founded, philanthropic donors and grantors have given more than $130 million for psychedelic and marijuana research and education. MAPS has earned both the Guidestar Platinum Seal of Transparency and a 4-Star Rating from Charity Navigator.

Founded in 1766, Christie’s is a world-leading art and luxury business. Renowned and trusted for its expert live and online auctions, as well as its bespoke private sales, Christie’s offers a full portfolio of global services to its clients, including art appraisal, art financing, international real estate and education. Christie’s has a physical presence in 46 countries, throughout the Americas, Europe, Middle East, and Asia Pacific, with flagship international sales hubs in New York, London, Hong Kong, Paris and Geneva. It also is the only international auction house authorized to hold sales in mainland China (Shanghai).

Christie’s auctions span more than 80 art and luxury categories, at price points ranging from $200 to over $100 million. In recent years, Christie’s has achieved the world record price for an artwork at auction (Leonardo da Vinci’s Salvator Mundi, 2017), for a 20th century artwork (Andy Warhol’s Shot Sage Blue Marilyn, 2022) and for a work by a living artist (Jeff Koons’ Rabbit, 2019). Christie’s is also recognised as a reference for prestigious single owner collections, having auctioned 8 of the 10 most important collections in history.

Christie’s Private Sales offers a seamless service for buying and selling art, jewellery and watches outside of the auction calendar, working exclusively with Christie’s specialists at a client’s individual pace.

Recent innovations at Christie’s include groundbreaking sale of the first NFT for a digital work of art ever offered at a major auction house (Beeple’s Everydays, March 2021), with the unprecedented acceptance of cryptocurrency as a means of payment. As an industry leader in digital innovation, Christie’s also continues to pioneer new technologies that are redefining the business of art, including the use of hologram technology to tour life-size 3D objects around the world, and the creation of viewing and bidding experiences that integrate augmented reality, global livestreaming, buy-now channels, and hybrid sales formats.

Christie’s is dedicated to advancing responsible culture throughout its business and communities worldwide, including achieving sustainability through net zero carbon emissions by 2030, and actively using its platform in the art world to amplify under-represented voices and support positive change. 

Browse, bid, discover, and join us for the best of art and luxury at: www.christies.com or by downloading Christie’s apps.

*Please note when quoting estimates above that other fees will apply in addition to the hammer price – see Section D of the Conditions of Sale at the back of the sale catalogue.

*Estimates do not include buyer’s premium. Sales totals are hammer price plus buyer’s premium and are reported net of applicable fees.

Posted on

MindMed Announces Completion of Share Redesignation

MindMed Announces Completion of Share Redesignation

NEW YORK, June 30, 2022 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (“MindMed” or the “Company”) announces that it has completed its previously announced redesignation of its subordinate voting shares as common shares (the “Common Shares”) of the Company. The Common Shares will be assigned CUSIP number 60255C802 and ISIN number CA60255C8025 following the redesignation. The Common Shares will begin trading on a post-redesignation basis under the new CUSIP and ISIN numbers on the NEO Exchange and NASDAQ at market open on July 4, 2022 and July 5, 2022, respectively, under the existing trading symbols. 

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

MindMed trades on NASDAQ under the symbol MNMD and on the NEO Exchange under the symbol MMED.

For Media: media@mindmed.co

For Investors: ir@mindmed.co

Cautionary Notes and Forward-looking Statements

This news release includes certain statements that constitute “forward-looking statements”, and “forward-looking information” within the meaning of applicable securities laws collectively “forward-looking statements”. These include statements regarding the Company’s intent, or the beliefs or current expectations of the Company’s officers and directors. When used in this new release, words such as “will”, “would”, “subject to”, “anticipates”, “at which time”, “will allow”, “pursue” and similar expressions are intended to identify these forward-looking statements as well as phrases or statements that certain actions, events or results “may”, “could”, “would”, “should”, “occur” or “be achieved” or the negative connotation of such terms. As well, forward-looking statements may relate to the Company’s future outlook and anticipated events, such as the expectation that the Common Shares will resume trading on July 4, 2022 on the NEO Exchange and July 5, 2022 on NASDAQ. Forward-looking statements are based on information available at the time those statements are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Forward-looking statements speak only as of the date those statements are made. Except as required by applicable law, the Company assumes no obligation to update or to publicly announce the results of any change to any forward-looking statement contained or incorporated by reference herein to reflect actual results, future events or developments, changes in assumptions or changes in other factors affecting the forward-looking statements. If the Company updates any one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect to those or other forward-looking statements. All forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Posted on

atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer

atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer

Dr. Chad Beyer will join as CEO on July 1, 2022

NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) — Kures Therapeutics, Inc (“Kures”), an atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”) company focused on developing treatment options to better manage addictions, depression, and pain, today announced the appointment of Chad E. Beyer, Ph.D., MBA, currently Senior Vice President of Research and Development at Promentis Pharmaceuticals, Inc (“Promentis”), as Chief Executive Officer of Kures, effective July 1, 2022.

Dr. Beyer has over 25 years of experience in the discovery, research and translational development of medications that treat the central nervous system and neurological disorders. He has led several preclinical and clinical drug discovery teams and participated in the submission of more than 30 INDs and provided supporting data for the commercialization and life-cycle management of two blockbuster medications. Dr. Beyer has authored more than 70 manuscripts and co-edited the book entitled “Next Generation Antidepressants” and co-founded the journal “Technology Transfer & Entrepreneurship.”

“Dr. Beyer has dedicated his career to advancing CNS treatments – and this dedication exemplifies our mission here at atai,” said atai Co-Founder and Chief Scientific Officer and outgoing Kures CEO, Srinivas Rao. “I can’t think of a better person to lead the Kures team into the next phase of its journey than Dr. Beyer, and I look forward to seeing what we can achieve together.”

Outgoing Kures CEO Dr. Srinivas Rao will continue to support and advise Kures’ programs from his role at atai Life Sciences.

About Kures Therapeutics
Kures is developing KUR-101 for the treatment of OUD. KUR-101 is a deuterated version of mitragynine, the major alkaloid in kratom that is a relatively low-potency mu-opioid receptor, or MOR, agonist. KUR-101 is a semisynthetically produced drug substance designed to improve the safety profile and potential effectiveness of mitragynine. In results from our preclinical studies carried out to date, KUR-101 has shown dose-dependent analgesic effect without inducing significant respiratory depression at therapeutic doses in animal models.

About atai Life Sciences 
atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. 

atai’s business model combines funding, technology, scientific, and regulatory expertise with a focus on innovative compounds, including psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients. 

atai’s vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life. 

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including without limitation, statements about our expectations relating to management transition changes and related timelines, statements regarding Kures (KUR-101), including the therapeutic potential of KUR-101, and similar statements of a future or forward-looking nature. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors discussed under the caption “Risk Factors” in atai’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as updated by atai’s subsequent filings with the SEC.

Any forward-looking statements made herein speak only as of the date of this press release, and you should not rely on forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, performance, or achievements reflected in the forward-looking statements will be achieved or will occur. Except as required by applicable law, we undertake no obligation to update any of these forward-looking statements for any reason after the date of this press release or to conform these statements to actual results or revised expectations.

Investor Contact

Greg Weaver
Chief Financial Officer
Greg.Weaver@atai.life

Media Contact

Allan Malievsky
Senior Director, External Affairs
allan@atai.life

Posted on

Heads of Agreement secured with leading pharma and healthcare products company, China Chemical & Pharmaceutical Co., Ltd. (“CCPC”) to launch Sierra Sage Herbs LLC (“SSH”) products for Taiwanese animal healthcare market

Heads of Agreement secured with leading pharma and healthcare
products company, China Chemical & Pharmaceutical Co., Ltd.
(“CCPC”) to launch Sierra Sage Herbs LLC (“SSH”) products for
Taiwanese animal healthcare market

Highlights:

  • Creso Pharma secures non-binding, non-exclusive Heads of Agreement (“HoA”) with China Chemical & Pharmaceutical Co., Ltd. (“CCPC”) (1701.TW)
  • This HoA provides potential for access to the rapidly growing Taiwanese animal healthcare market and underpins Creso Pharma’s international expansion
  • CCPC is focused on innovation, research & development, and manufacturing of pharmaceutical and healthcare products for use in humans and animals
  • CCPC is a publicly traded company on the Taiwan Stock Exchange, with a market capitalisation of over A$321Mi
  • CCPC has a dedicated animal healthcare division and sales team which works directly with veterinarians throughout Taiwan
  • Products to be selected from the Sierra Sage Herbs range with initial focus on SSH’s innovative, plant-based Animal First Aid
  • HoA has the potential to provide scope for Creso Pharma and CCPC to expand the range of current and future products for collaboration
  • Creso Pharma and CCPC are working towards establishing a Collaborative Agreement on or before 31 August 2022, unless extended by agreement between the parties
  • Taiwan has a growing petcare market – spending on pet care related products, which rose from US$283.2m to US$402.9m in 2019ii

Creso Pharma Limited (ASX:CPH, OTC:COPHF, FRA:1X8) (‘Creso Pharma’ or ‘the Company’)
is pleased to advise that it has secured a non-binding, non-exclusive Heads of Agreement (“HoA”) with leading pharma and healthcare products company, China Chemical & Pharmaceutical Co., Ltd. (“CCPC”) for the introduction of Sierra Sage Herbs LLC products to the Taiwanese animal healthcare market. The HoA intends to broaden Creso Pharma’s international exposure and provides the Company with an established in-country partner to potentially drive sales growth.

Founded in 1952, China Chemical & Pharmaceutical Co., Ltd. is a publicly listed company
(1701.TW), with a market capitalisation of ~A$321Mi The company is dedicated to innovation, research and development, and manufacturing of pharmaceutical and healthcare products for use in humans and animals. CCPC has its own in-house sales team directly servicing veterinary clinics with animal medications throughout Taiwan.

Under the HoA, the parties have agreed to enter into a Collaborative Agreement on or before 31 August 2022 (“Expiration Date”), with the parties being able to extend this timeframe by mutual agreement (“Collaborative Agreement”). The HoA can be terminated upon either party giving written notice at any time prior to the execution of a Collaborative Agreement. There has been no consideration set between the parties under the HoA.
This Collaborative Agreement is intended to set out the terms upon which Creso Pharma and CCPC will:

  1. Commercialise select products from Creso Pharma’s target acquisition company, Sierra Sage Herbs’ (SSH) pet care product range in the Taiwanese market. The initial focus will be on SSH’s Animal First Aid product.
  2. Explore further commercialisation options for current and future innovative products.
    Product interest extends to Animal Pain Relief, Animal Castile Wash, Bugs Be Gone and
    potential future innovative products from SSH/Creso Pharma’s product development
    pipeline.

The pet care market presents a market opportunity for Creso Pharma and SSH, due to the increase in more young Taiwanese choosing to own and raise pets instead of having childrenii. This has led to considerable increased spending on pet care related products, which rose from US$283.2m to US$402.9m in 2019iii.

About Sierra Sage Herbs Pet Care Products

SSH salves are fundamentally different from other products on the market. SSH’s herbs are
carefully sourced from organic farmers, with the products’ defining characteristic being a lipidinfusion process. Rather than using pre-made extracts, SSH infuses fresh and dried herbs in organic oils over low heat for an extended amount of time to maximise the potency and purity of the products.

Green Goo Animal First Aid’s powerful formula is fortified with calendula, yarrow, and comfrey to help soothe and repair minor wounds. It’s portable first aid for all domesticated animals.

Green Goo Animal First Aid: First SSH product planned for launch in Taiwan.

Commentary:

CEO and Managing Director of Creso Pharma, William Lay said: “CCPC is one of Taiwan’s
leading healthcare companies. Their products are widely used in hospitals and households
throughout Taiwan, which has led them to becoming a trusted provider. We’re delighted to
collaborate with such a great partner on developing a brand new market for our animal care
products. We view this development as a testament to the broader opportunity we see for the Green Goo range in other international markets.”

CEO and Co-Founder of Sierra Sage Herbs Jodi Scott said: “Pet parents love our Green Goo
products because they are all natural, plant based and highly effective. We’re delighted with the feedback we have received from product evaluations in Taiwan and are grateful for the great work done by CCPC to get us to this stage.”

Director of Animal Health Division of CCPC, Jason Wang said: “We are delighted to reach this milestone in our collaboration with Creso Pharma. The all-natural Green Goo product range is right on trend with expectations from pet owners in Taiwan and we are committed to maximising the potential of these great products.”

Posted on

Ketamine Wellness Centers (KWC) Launches Ketamine Wellness Integrative Therapist Directory

Ketamine Wellness Centers (KWC) Launches Ketamine Wellness Integrative Therapist Directory

Nation’s Largest Ketamine Therapy Provider Offers Complimentary Patient Resource Supporting Holistic Mental Health Treatment

GILBERT, AZ, June 30, 2022 – Ketamine Wellness Centers (KWC), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), today officially launched the Ketamine Wellness Integrative Therapist Directory. The comprehensive resource will connect KWC patients with qualified mental health practitioners who can help them process and integrate the benefits of ketamine therapy into their everyday life.  

The Ketamine Wellness Integrative Therapist Directory is available to anyone visiting KWC’s website. Cognitive therapists practicing in KWC’s operating states will also have the opportunity to join the network at no cost and more therapists will be added in the future. Patients utilizing KWC’s latest resource can reach out to local mental healthcare providers qualified to help individuals integrate ketamine therapy into their treatment plans. All providers or organizations listed included in the referral network align with KWC’s standards and philosophies of care. 

KWC continues to establish itself as a leading mental health treatment provider by offering various methods of accessible care, including ketamine therapy, cognitive therapy and NAD+ infusion therapy. Through its efforts, the company is approaching 100,000 treatments to clinically eligible patients across Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas, Utah and Washington.

“Ketamine therapy is a rapidly growing medical field demonstrating promising results, but many patients overlook the importance of continuous cognitive therapy after their ketamine treatments to maximize the outcomes,” said Kevin Nicholson, CEO of KWC and COO of Delic. “A therapist from the network can work with patients to bridge the outcomes from their completed ketamine therapy into positive, long-term changes in attitudes and behavior. By putting together a comprehensive list of like-minded, qualified mental health professionals and organizations, KWC is continuing to focus on a holistic approach to healing patients suffering from various mental health conditions.”

For more information about Ketamine Wellness Centers’ locations, services and hours of operation, please visit https://www.ketaminewellnesscenters.com/locations/.

About Ketamine Wellness Centers

Ketamine Wellness Centers (KWC) is the largest ketamine therapy provider in the United States with 13 clinic locations serving communities across nine states. Since 2011 KWC has been a trusted leader in bringing IV ketamine therapy into mainstream health care. KWC is approaching 100,000 treatments to clinically eligible patients, from young adults to seniors, in addition to developing specialized programs for veterans and first responders. The KWC team, including a core group of physicians, psychologists, clinicians, and executives, is dedicated to providing value-based, personalized, clinically controlled ketamine infusion care for people suffering from treatment-resistant depression, anxiety, PTSD, OCD and chronic pain. KWC’s scalable business and treatment model is designed for further rapid expansion along with breakthrough innovations in effective therapies and services.

About Ketamine Wellness Integrative Therapist Directory

Ketamine Wellness Centers has met with the providers listed to ensure aligned standards and philosophies of care. However, this list is provided for informational purposes only and should not be construed as a referral by KWC to any specific provider. KWC does not make any express or implied warranties, representations, or endorsements of this list and has not had the credentials or representations within any providers’ listing independently verified. This list includes licensed individuals who identify as being knowledgeable proponents of ketamine integrative care. The practitioners listed represent a variety of modalities, please use your discretion to find a practitioner who meets your specific needs.   Additionally, Ketamine Wellness Centers shall have no responsibility or liability for any damage or loss caused or alleged to be caused by or in connection with use of or reliance on any services available on or through the Integrative Therapy List.

About Delic Corp

Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses.

Investor Relations Contact
Rich Rodriguez 
rich@deliccorp.com

Media Contact
MATTIO Communications
Clare Redlick 
delic@mattio.com

Posted on

Filament Health Announces Private Placement Of Units And Convertible Debenture Units Of Up To $2,500,000

Filament Health Announces Private Placement Of Units And Convertible Debenture Units Of Up To $2,500,000

Financing driven by psychedelic investment fund Negev Capital and leading functional mushroom manufacturer Nammex

Vancouver, British Columbia, June 30, 2022  – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, is pleased to announce that it intends to complete, subject to regulatory approval, a non-brokered private placement for gross proceeds of up to C$2,500,000 (the “Offering”). 

The Offering includes a non-brokered private placement of up to 1,250 convertible debenture units of the Company (the “Convertible Debenture Units”) at a price of $1,000 per Convertible Debenture Unit for gross proceeds of up to $1,250,000 (the “Convertible Debenture Unit Financing”) and a non-brokered private placement of up to 9,616,000 units (the “Units”) at a price of $0.13 per Unit for gross proceeds of up to $1,250,080 (the “Unit Financing”).

“This is an important development for Filament which amplifies our position at the forefront of botanical drug discovery,” said Benjamin Lightburn, Chief Executive Officer and Co-Founder at Filament Health. “We are thrilled to partner with high quality investors like Nammex and Negev and welcome the enhancements they will bring to our Board of Directors and Advisory Council, as well as our long-term shareholder base.”

“Negev Capital is excited to support Filament Health, among the most compelling  early-stage companies in the psychedelic space,” said Ken Belotsky, Partner at Negev Capital. “We are especially impressed with Filament’s creative, energetic, and strategic management team, strong IP, manufacturing and extraction expertise, and impressive partnerships. We are delighted to support their drug development strategy as they thoughtfully develop psychedelic treatments that can positively impact millions of lives.”

The Company intends to use the net proceeds of the Offering for drug discovery and development, intellectual property initiatives, working capital and other general corporate purposes. Closing of the Offering is expected to occur on or about July 14, 2022, and remains subject to the final approval of the NEO Exchange.

“We have been following Filament’s story over the past few years and are impressed by the team’s rapid progress and technical capabilities,” said Jeff Chilton, President of Nammex. “We are pleased to partner with another industry leader in botanical extraction, and are thrilled to help facilitate Filament’s growth.”

The Company also announced that the founders of Filament Health, Mr. Lightburn, Tom Kineshanko, and Joel Sherlock, have voluntarily extended their lock-up for all of their common shares for a period of 24 months, subject to limited exceptions. These shares represent approximately 67% of Filament’s outstanding common shares. 

UNIT FINANCING

The Unit Financing is led by Nammex whose founder, Mr. Chilton, will join Filament’s Advisory Council. For over 30 years, Nammex has specialized in the development and manufacture of functional mushroom extract powders and is the premier supplier of organically certified mushroom extracts for the health and wellness industry.

Each Unit will consist of one Common Share and one common share purchase warrant (the “Warrants”) of the Company. Each Warrant will be exercisable to acquire one common share of the Company (a “Common Share”) for a period of 36 months following the closing date of the Offering at an exercise price of $0.30 per Common Share, subject to adjustment in certain events. The Unit Financing investors have agreed to sign a voluntary lock-up for all of the common shares for a period of 12 months.

CONVERTIBLE DEBENTURE UNIT FINANCING

Negev Capital, a psychedelic medical intervention investment fund that has made 20 investments to date, is the sole investor in the Convertible Debenture Unit Financing. The Company has also agreed to nominate a member of Negev Capital to Filament’s Board of Directors, within 30 days post-closing.

Each Convertible Debentures Unit will consist of $1,000 principal amount of unsecured convertible debentures (the “Convertible Debentures”) and 6,667 Warrants of the Company. Each Convertible Debenture will be convertible into Common Shares at a conversion price of $0.15 per Common Share. Each Warrant will be exercisable to acquire one Common Share for a period of 36 months following the closing date of the Offering at an exercise price of $0.30 per Common Share, subject to adjustment in certain events.

The Convertible Debentures are non-interest bearing and shall mature on the date that is the earlier of: a) 24 months from the date of issuance; or b) on the date the Company completes a financing of $5,000,000 or greater. Upon a change of control of the Company, holders of Convertible Debentures will have the right to require the Company to repurchase their Convertible Debentures, in whole or in part, on the date that is 30 days following notice of the change of control at a price equal to 105% of the principal amount of the Convertible Debentures then outstanding plus accrued and unpaid interest thereon.

Negev Capital has agreed to sign a voluntary lock-up agreement, consistent with the founders of Filament, for a period of 24 months, subject to certain exceptions.

The Common Shares, Warrants and Convertible Debentures, and any securities into which they may be exchanged or converted, will be subject to resale restrictions imposed by applicable securities laws, including a statutory hold period expiring four months and one day from the date of closing. The Offering is subject to approval from the NEO.

The offered securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold to, or for the account or benefit of, any person in the United States or any “U.S person”, as such term is defined in Regulation S under the Securities Act, absent registration or an applicable exemption from registration requirements. Offers and sales in the United States will be limited to institutional accredited investors. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

ABOUT FILAMENT HEALTH (OTCQB:FLHLF) (NEO:FH) (FSE:7QS)

Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.

Learn more at www.filament.health and on Twitter, Instagram and LinkedIn

FILAMENT HEALTH

Anna Cordon, Director of Communications
778.245.9067
anna@filament.health

INVESTOR RELATIONS

ir@filament.health

FORWARD LOOKING STATEMENTS

Certain statements and information contained herein may constitute “forward-looking statements” and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward-looking statements or information. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking statements discussed in this press release may include, but are not limited to, information concerning the impact of the patent on the Company’s business and the ability of the Company to secure future patents. Forward-looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including status of patent applications and the ability to secure patents. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.30

Posted on

Pure Extracts Signs Listing Agreement With Shoppers Drug Mart and Receives Initial Purchase Order

Pure Extracts Signs Listing Agreement With Shoppers Drug Mart and Receives Initial Purchase Order

Vancouver, B.C., June 30, 2022 – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging psychedelic sector, is pleased to announce that its wholly-owned subsidiary, Pure Extracts Manufacturing Corp., has signed a Cannabis Products Supplier Agreement with Medical Cannabis by Shoppers Drug Mart Inc. (“Shoppers”).

The initial purchase order (PO) comprises 6 SKUs including Pure Pulls™ THC and CBD full spectrum oil (FSO) vape cartridges, as well as Pure Chews™ THC and CBD edible gummies. The gummies are sold in Pure Extracts’ proprietary blister packages for ultimate freshness and convenience. These products will be made available on the Medical Cannabis by Shoppers™ platform.

Pure Extracts’ CEO, Ben Nikolaevsky, remarked, “We are excited about joining such a trusted health and wellness retailer as Shoppers and look forward to introducing our brands to their medical customers. This marks another successful milestone in the expansion of our line of branded products and we believe this distribution relationship will contribute a significant amount of revenue to our financials over time.”

About Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)

Pure Extracts features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act on September 25, 2020, and its Sales Amendment on July 19, 2021. The Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.

Find out more at https://pureextractscorp.com/

Or contact:
Pure Extracts Investor Relations
Tel: +1 604 493 2052
info@pureextractscorp.com    

ON BEHALF OF THE BOARD

“Ben Nikolaevsky”
Ben Nikolaevsky
CEO and Director

This news release contains forward-looking statements relating to the future operations of Pure Extracts,

and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Risk Factors” in the Company’s Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

This news release contains information about potential sales revenue from supply agreements, which may be considered as disclosure of financial outlook under applicable securities laws. Such information is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. Specifically, estimated sales revenue which may be derived from supply contracts has been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. Financial outlook contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the potential revenue which may be derived from supply agreement recently entered into by the Company, and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.

Posted on

PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

Successfully delivered ketamine and KETABET™ (ketamine and betaine) via microneedle patch, unlocking the potential for desired dosage forms and pharmacokinetic profiles

Pursuing Phase 2 clinical studies in treatment-resistant depression and pain indications in Q4-2022

TORONTO, June 29, 2022 — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that it has successfully completed its research study evaluating the Company’s patented hydrogel-forming microneedle patch, PHARMAPATCH™, to deliver ketamine and KETABET™ (ketamine and betaine anhydrous), which aims to prevent the potential side effects of repeated ketamine treatment for depression and other indications, including suicidal ideation, substance abuse, post-traumatic stress disorder, neurological disorders, and chronic pain.

PHARMAPATCH™ has been shown to successfully deliver esketamine, the S(+) enantiomer of ketamine, which may overcome the drawbacks associated with ketamine administration in an intravenous or nasal spray format. Research results were published in a paper titled “Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery”1.

The aim of the research program led by Prof Ryan Donnelly at Queens University Belfast (“QUB”) was to develop and characterize PHARMAPATCH™ for the transdermal delivery of ketamine and KETABET™ in a sustained manner and finalize production scale-up processes for clinical studies. Characterization of drug recovery and stability before drug permeation from films via hydrogel-forming microneedle array patches (“MAP”) was assessed in vitro using the Franz cell apparatus. Based on the findings from in vitro permeation investigations, lead candidate MAP formulations were selected and brought forward for in vivo testing using Sprague-Dawley rats to assess the ability to achieve sustained plasma concentrations of ketamine and betaine within the therapeutic range for potential antidepressant therapy over the course of 48 hours.

PHARMAPATCH™ is an alternative platform that allows ketamine to be delivered transdermally in a sustained and de-risked manner. The results from this study represent the first time that multiple formulations of PHARMAPATCH™ for the delivery of ketamine and betaine have been developed, characterized and tested in an animal model. Extensive characterisation of each drug-containing polymeric film and hydrogel-forming MAP combination in terms of swelling capacity, insertion capabilities, drug recovery, stability, and ultimately in vitro drug permeation using the Franz cell apparatus allowed the selection of the most promising candidate formulations for in vivo testing. Hydrogel-forming MAP-mediated delivery of ketamine and betaine were compared with intramuscular injection and orally administered solution, respectively. At regular time intervals during the 48-hour rat study, blood sample results demonstrated that PHARMAPATCH™ was able to deliver plasma levels of ketamine (between 70-200 ng/mL) in a controlled manner throughout the study.

The findings of this work support PHARMAPATCH™ as a promising drug delivery platform through which effective, de-risked, and safe ketamine therapies can be delivered. Considering the high degree of flexibility possessed by this delivery system in terms of formulation, the potential for effective treatment regimens extending beyond 48 hours could be developed through further alterations in surface area, application time, and drug loading of these polymeric patches. 

The Company is preparing for a planned Phase 2 clinical study to allow for ketamine and KETABET™ microneedle patch evaluation in treatment-resistant depression and chronic pain under the FDA 505(b)(2) regulatory pathway. The Company is manufacturing its ketamine microneedle patches at LTS LOHMANN Therapie-Systeme AG for upcoming GLP pre-clinical pig studies to demonstrate the delivery, dosing and safety profile of ketamine in a comparable animal model to support regulatory filings to conduct human clinical studies in Q4-2022. In addition, scale up of the manufacturing process to support GMP and commercial production is currently underway.

About PHARMAPATCH™    

Microneedle-enhanced intradermal delivery is an elegant, efficient and painless method for increasing the skin permeation of many drugs, including ketamine. Transdermal delivery systems offer several advantages over inhalation and intravenous administration. PharmaTher‘s approach with ketamine consists of a 2-part system comprised of a drug-loaded reservoir placed on top of the hydrogel microneedle array. After administration into the skin (i.e. intradermal delivery), the microneedles become hydrated and swell, creating pores for the reservoir to release the drug content into the tissue over the treatment course. Upon removal, the needles are intact, yet rounded, and do not need to be disposed of as sharps. The drug enters the systemic circulation circumventing absorption and first-pass barriers typical for oral delivery. Studies have shown that systemic drug concentrations are reached minutes after administration and maintained over multiple days with transdermal delivery. This system addresses a major unmet need by offering greater ease of administration and including patients with pre-existing conditions that exempt them from oral or inhalation dosing. In addition, it avoids syringe needles, eliminating pain and patient visits to a clinician.

Potential of the Ketamine Microneedle Patch

The Company’s patented hydrogel-forming microneedle (“MN”) patch aims to deliver ketamine for intradermal administration to treat various mental health, neurological and pain disorders. The MN patch consists of hydrogel-forming microneedle arrays and an accompanying reservoir that will overcome limitations by the quantity of drug loaded into the needles or onto the needle surfaces. As such, the MN patch can significantly increase the amount of drug that can permeate through the microneedle array and into the skin.2 The MN patch is tailored for ketamine due to the required drug volume to maximize their therapeutic utility and increase potential market opportunities.

The ketamine MN patch aims to empower patients to dose their medication remotely, safely and conveniently rather than being supervised by a healthcare provider at a certified medical office. The ketamine MN patch has the potential for enabling continuous delivery of ketamine (without pain) with minimal formulation manipulation into systemic circulation while maintaining constant plasma levels for more than 24 hours, which will improve efficacy and compliance for patients.1-2 Also, the ketamine MN patch will incorporate anti-tampering and anti-abuse features that parallel the approach used by commercially available tamper-resistant transdermal fentanyl patches.

About PharmaTher Holdings Ltd.

​PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the development and commercialization of specialty ketamine pharmaceuticals for mental health, neurological, and pain disorders. Learn more at PharmaTher.com.

For more information about PharmaTher, please contact:

Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “potential”, “aim”, “may” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmaTher Holdings Ltd. (the “Company”) current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the three and nine month periods ended February 28, 2022 and 2021 (“MD&A”), dated April 25, 2022, which is available on the Company’s profile at www.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

Sources:
1.Courtenay, et al. Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery, Journal of Controlled Release, Volume 322, 2020, Pages 177-186.

2.     Donnelly R.F. Hydrogel-forming microneedles prepared from “super swelling” polymers combined with lyophilised wafers for transdermal drug delivery. PLoSONE. 2014 doi: 10.1371/journal.pone.0111547.